Xtalks
Beyond ctDNA: EVPs and the Future of Early Cancer Detection, Upcoming Webinar Hosted by Xtalks
In this free webinar, explore the potential of extracellular vesicles and particles (EVPs) as liquid biopsy analytes for early cancer detection.…
Category
Biotech & Pharma press releases
61 releases
Xtalks
Advancing Diabetes Clinical Trials Through Integrated Technology and Operational Oversight, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how integrated technology and coordinated operational oversight can support diabetes clinical trial execution. The…
Galderma
Galderma launches ALASTIN Restorative Eye Complex with TriHex+™, bringing new science-backed innovation to the entire eye area
Restorative Eye Complex is now formulated with TriHex+™, which pairs ALASTIN's TriHex Technology® to support the body's natural processes for…
Anixa Biosciences, Inc.
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond…
Ideal Option
Ideal Option Releases 2025 Patient Outcomes Annual Report, Highlighting Life-Saving Treatment Amid Alaska's Ongoing Overdose Crisis
New data show 97% opioid abstinence rates among long-term patients in Alaska as state faces high overdose death rates and persistent polysubstance…
TJ Biopharma
TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading…
Evogene
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain REHOVOT,…
Duchesnay inc.
Initiation of a Phase III Clinical Study of BON-001 for Nausea and Vomiting of Pregnancy in Japan
Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo, Japan; President: Naoyuki Mochida; hereinafter "Mochida") and Duchesnay Inc. (Head…
Compugen Ltd.
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered…
Climb Bio, Inc.
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data;…
DropGenie
DropGenie Secures $5 Million Seed+ Financing to Scale Functional Biology Platform and Data Partnerships
New capital brings primary-cell functional data to more discovery teams, on demand MONTREAL, Oct. 26, 2026 — DropGenie, a functional biology company…
WuXi AppTec
WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model
WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing…
Innovent Biologics
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high…
Zinzino
ZINZINO AB (PUBL): Zinzino launches fermented botanical supplements for morning, day and evening
European launch of BelAgeAM, Inner7 and KroNuitPM combines fermented ingredients with convenient drink formats as wellness becomes an increasingly…
Likang Life Sciences
ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan's Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC
On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at the Cancer Hospital, Chinese Academy of…
Innovent Biologics
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant…
Kelun-Biotech
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65;…
Eli Lilly and Company
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy…
Johnson & Johnson
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between…
Innovent Biologics, Inc.
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and…